Tim Cortese - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Tim Cortese's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Tim Cortese
Verified
Assistant Editor, MJH Life Sciences
Oakl
Beats
Aged Care Nursing Health Care
Crime, Entertainment
Content
By Tim Cortese| ONCOLOGY journal Verified Fruquintinib (Fruzaqla) plus best supportive care exhibited a manageable and expected safety profile in the treatment of patients with pretreated metastatic colorectal cancer (CRC), according to a safety analysis of the phase 3 FRESCO-2 trial (NCT04322539).1The most common any-grade treatment-related adverse events (TRAEs) with fruquintinib were hypertension (28.9%), asthenia (24.6%), palmar-plantar erythrodysesthesia (PPE) syndrome (18.6%), diarrhea (18.0%), and decreased appetite (16.0%).
By Tim Cortese| ONCOLOGY journal Verified Cemiplimab-rwlc (Libtayo) continued to show long-term, durable clinical benefits when compared with chemotherapy in the first-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with PD-L1 expression in 50% or more of tumor cells, according to 5-year follow-up results from the phase 3 EMPOWER-Lung 1 trial (NCT03088540) published in the Journal of Thoracic Oncology.1With a median follow-up for the total study population was 59.6 months (IQR, 55.1-66.7).
By Tim Cortese| ONCOLOGY journal Verified Fruquintinib (Fruzaqla) plus best supportive care exhibited a manageable and expected safety profile in the treatment of patients with pretreated metastatic colorectal cancer (CRC), according to a safety analysis of the phase 3 FRESCO-2 trial (NCT04322539).1The most common any-grade treatment-related adverse events (TRAEs) with fruquintinib were hypertension (28.9%), asthenia (24.6%), palmar-plantar erythrodysesthesia (PPE) syndrome (18.6%), diarrhea (18.0%), and decreased appetite (16.0%).
Company Info
MJH Life Sciences
NeurologyLive is a multimedia platform focused on delivering the latest news and insights in the field of neurology. It serves as a valuable resource for healthcare professionals, particularly those treating neurological diseases. The platform offers a combination of print and digital media, ensuring that busy clinicians stay informed about significant developments in neurology. The services provided by NeurologyLive include breaking news on drug approvals, clinical trials, and emerging trends in neurological care. It features expert interviews with leading neurologists, offering insights into the latest research and clinical practices. The use of multimedia content makes the information accessible and engaging for its audience. NeurologyLive targets healthcare professionals such as neurologists, clinicians, and researchers. It has established strategic partnerships with organizations like the Consortium of Multiple Sclerosis Centers, enhancing its credibility and reach within the neurology community. Its comprehensive coverage and expert engagement position NeurologyLive as a trusted source for the latest developments in the field.
Cranbury, United States
+1 609-716-7777
Founded: 2018